v3.25.2
Long-Term Investments (Details) - USD ($)
6 Months Ended 12 Months Ended
Oct. 31, 2021
Jun. 30, 2025
Dec. 31, 2024
Dec. 31, 2022
Mar. 14, 2024
Long-Term Investments [Line Items]          
Percentage of common stock shares 51.00% 37.00%      
Aggregate amount   $ 7,670,000   $ 2,688,578  
Prepayment amount       $ 1,895,556  
Converted shares   994,450      
Common stock, shares authorized   100,000,000 100,000,000    
Ordinary shares issued   19,533,416 13,868,484   1,610,700
Ordinary shares outstanding   19,533,416 13,868,484    
Payment to joint venture $ 150,000        
BioFirst Corporation [Member]          
Long-Term Investments [Line Items]          
Percentage of common stock shares   18.68% 18.68%    
Prepayment amount     $ 1,124,842    
Ordinary shares issued 3,049        
Ordinary shares outstanding 3,049        
Rgene Corporation (the “Rgene”) [Member]          
Long-Term Investments [Line Items]          
Percentage of common stock shares   26.65%      
BioLite Japan K.K. [Member]          
Long-Term Investments [Line Items]          
Percentage of common stock shares 49.00%        
Common stock, shares authorized 10,000        
Payment to joint venture $ 150,000        
BioLite JP [Member]          
Long-Term Investments [Line Items]          
Owned shares 1,494        
Common Stock [Member]          
Long-Term Investments [Line Items]          
Aggregate amount        
Common Stock [Member] | Lucidaim Co Ltd [Member]          
Long-Term Investments [Line Items]          
Owned shares 1,555